Last viewed: BLUE


Prices are updated after-hours



nasdaq:BLUE bluebird bio, Inc.

BLUE | $7.24 | twitter stocktwits trandingview |
Health Technology

(0.0% 1d) (-36.5% 1m) (-84.9% 1y) (4.5% 2d) (-4.1% 3d) (-8.5% 7d) (113.39% volume)
http://www.bluebirdbio.com
Sec Filling | Patents | 1090 employees

bluebird bio, Inc. is a clinical-stage biotechnology company, which engages in the development of potential gene therapies for severe genetic diseases and cancer. Its integrated product platform includes gene therapy, cancer immunotherapy, and gene editing. Its product pipeline includes Lenti-D, LentiGlobin, BCL11a shRNA, bb2121, and bb21217. The company was founded by Philippe Leboulch and Ronald C. Dorazio on April 16, 1992 and is headquartered in Cambridge, MA.

add to today's watch list email alert is off




cancer   gene therapies   immunotherapy   genetic  

Press-releases


bluebird Provides Update on FDA Review Timelines for Betibeglogene Autotemcel (beti-cel) for Beta-Thalassemia and Elivaldogene Autotemcel (eli-cel) for Cerebral Adrenoleukodystrophy (CALD)
Published: 2022-01-18 (Crawled : 12:30) - biospace.com/
BLUE | $7.24 | twitter stocktwits trandingview |
Health Technology
| | O: -3.19% H: 1.0% C: -6.94%

fda cel
Outlook on the CAR T-cell Therapy Global Market to 2031 - by Product Type, Indications, End-user and Region
Published: 2022-01-14 (Crawled : 14:00) - prnewswire.com
NVSEF | News | $88.6 | twitter stocktwits trandingview |
Health Technology
| | O: 1.26% H: 0.0% C: 0.0%
SRNE | $3.805 | twitter stocktwits trandingview |
Health Technology
| | O: -5.96% H: 0.0% C: 0.0%
NVS | News | $87.83 | twitter stocktwits trandingview |
Health Technology
| | O: 0.02% H: 0.0% C: 0.0%
GILD | $68.51 | twitter stocktwits trandingview |
Health Technology
| | O: -0.32% H: 0.0% C: 0.0%
BLUE | $7.24 | twitter stocktwits trandingview |
Health Technology
| | O: -0.57% H: 0.0% C: 0.0%
JNJ | News | $165.98 | twitter stocktwits trandingview |
Health Technology
| | O: -0.53% H: 0.0% C: 0.0%

era cel therapy t-cell
bluebird bio to Provide Update on Program Milestones and 2022 Financial Outlook at the 40th Annual J.P. Morgan Healthcare Conference
Published: 2022-01-11 (Crawled : 13:00) - biospace.com/
BLUE | $7.24 | twitter stocktwits trandingview |
Health Technology
| | O: 2.34% H: 0.0% C: 0.0%


bluebird bio to Present at the 40th Annual J.P. Morgan Healthcare Conference
Published: 2022-01-05 (Crawled : 13:30) - biospace.com/
BLUE | $7.24 | twitter stocktwits trandingview |
Health Technology
| | O: -0.39% H: 2.64% C: -3.22%

health thc conference j.p. morgan healthcare conference
bluebird bio Announces Partial Clinical Hold for Patients Under 18 in Sickle Cell Gene Therapy Clinical Program
Published: 2021-12-20 (Crawled : 13:30) - biospace.com/
BLUE | $7.24 | twitter stocktwits trandingview |
Health Technology
| | O: -9.24% H: 27.28% C: 26.75%

clinical hold ces gene therapy era cel therapy
2seventy bio Reports Third Quarter Financial Results and Recent Operational Progress
Published: 2021-12-01 (Crawled : 12:30) - biospace.com/
TSVT | $20.07 | twitter stocktwits trandingview |
| | O: -0.65% H: 10.47% C: 1.26%
BLUE | $7.24 | twitter stocktwits trandingview |
Health Technology
| | O: 0.39% H: 5.38% C: -1.66%

financial results results
bluebird bio Announces FDA Priority Review of Biologics License Application for beti-cel Gene Therapy for Patients with β-thalassemia Who Require Regular Red Blood Cell Transfusions
Published: 2021-11-22 (Crawled : 14:30) - biospace.com/
BLUE | $7.24 | twitter stocktwits trandingview |
Health Technology
| | O: 5.7% H: 0.44% C: -6.81%

fda blood transfusion application gene therapy therapy license
AavantiBio Further Enhances Leadership Team with Appointment of Jenny Marlowe, Ph.D. as Chief Scientific Officer
Published: 2021-11-16 (Crawled : 14:00) - biospace.com/
IBIO | $0.44 | twitter stocktwits trandingview |
Health Technology
| | O: -6.01% H: 0.0% C: 0.0%
NVS | News | $87.83 | twitter stocktwits trandingview |
Health Technology
| | O: -0.05% H: 0.14% C: -0.82%
BLUE | $7.24 | twitter stocktwits trandingview |
Health Technology
| | O: -2.25% H: 0.0% C: 0.0%


bluebird bio Reports Third Quarter Financial Results and Recent Operational Progress
Published: 2021-11-05 (Crawled : 12:00) - biospace.com/
BLUE | $7.24 | twitter stocktwits trandingview |
Health Technology
| | O: -29.61% H: 0.0% C: 0.0%
FRT | $123.22 | twitter stocktwits trandingview |
Finance
| | O: 1.56% H: 3.77% C: 1.48%

financial results results
2seventy bio Completes Spin Transaction and Launches Innovative Immuno-oncology Cell Therapy Company
Published: 2021-11-04 (Crawled : 12:00) - biospace.com/
JNJ | News | $165.98 | twitter stocktwits trandingview |
Health Technology
| | O: -0.13% H: 0.0% C: 0.0%
BLUE | $7.24 | twitter stocktwits trandingview |
Health Technology
| | O: 0.24% H: 0.0% C: 0.0%

therapy
See all


Last 15 days Sec forms
File Id Form Date Direction Code Amount Transacted Owned Amount


Your Today's Watch List
Sign in to create a watchlist
Today's Insiders Buying

Yesterday's Insiders Buying